Vidcast:  https://youtu.be/gErB1wj_36w

 

Localized bladder cancer that has not invaded the bladder muscle is often treated with tumor removal followed by topical chemotherapy or passive immunotherapy.  Now, the FDA has just improved gene bladder cancer therapy offered by Ferring Pharmaceuticals. And its FerGene spinoff.  The therapy, to be marketed under the Adstiladrin brand, uses an adenovirus carrier to introduce a gene into bladder lining cells that turns them into micro-factories capable of cranking out the cancer cell killer interferon-alpha-2b.

 

https://www.ferring.com/ferring-receives-approval-from-u-s-fda-for-adstiladrin-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer/

 

#genetherapy #bladdercancer #ferring #interferonalpha2b #fda